Change in target lesion sum of longest diameters from post-chemotherapy baseline to post-chemotherapy nadir
| Length of SLD Reduction (mm) | BTH1677/Bevacizumab/Carboplatin/Paclitaxela(N = 30) | Bevacizumab/Carboplatin/Paclitaxela(N = 13) |
|---|---|---|
| > 20 | 2 (7%) | 0 |
| > 10 | 6 (20%) | 0 |
| > 5 | 10 (33%) | 2 (15%) |
Abbreviations: N overall sample size, SLD sum of longest diameters
aNumber of patients continuing in study on maintenance therapy with at least 2 post-chemotherapy tumor assessments based on blinded central radiology review of the primary efficacy population